Skip to main content
SpringerLink
Log in

Management of Overt Diabetic Kidney Disease and Uremia

  • Chapter
  • First Online:
Managing Diabetic Nephropathies in Clinical Practice

  • 776 Accesses

Abstract

Once long-standing diabetes has involved the kidneys, the process of ongoing damage to predominantly glomerular structures cannot be stopped by currently available therapeutic interventions. Kidney damage is considered to be clinically “silent” (lacking obvious symptoms) and may present in two forms. Most commonly, proteinuria, starting as microalbuminuria, is the leading presentation. However, in approximately one in every seven patients, a reduction in estimated glomerular filtration (eGFR), without any type of albuminuria, is the first sign of kidney involvement in diabetes [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes. 2006;55:1832–9.

    Article  CAS  PubMed  Google Scholar 

  2. Mottl AK, Kwon KS, Mauer M, Mayer-Davies EJ, Hogan SL, Kshirsagar AV. Normoalbuminuric diabetic kidney disease in the U.S. population. J Diabetes Complications. 2013;27:123–7.

    Article  PubMed  Google Scholar 

  3. American Diabetes Association. Summary of revisions. In: standards of medical care in diabetes – 2016. Diabetes Care. 2016;39(Suppl1):S4–5.

    Google Scholar 

  4. Menke A, Casagrande S, Geiss L, Cowie C. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314:1021–9.

    Article  CAS  PubMed  Google Scholar 

  5. Bailey RA, Wang Y, Zhu V, Rupnow FT. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014;7:415.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter. 2013;3(Suppl.):1–150.

    Google Scholar 

  7. Noubiap JJ, Naidoo J, Kenge AP. Diabetic nephropathy in Africa: a systematic review. World J Diabetes. 2015;6:759–73.

    Article  PubMed  PubMed Central  Google Scholar 

  8. United States Renal Data System 2014 Annual Data Report. Volume 1, Chapter 1: CKD in the general population. www.usrds.org/2014/view/Default.aspx. Accessed 7 Mar 2016.

  9. United States Renal Data System 2014 Annual Data Report. Volume 2, Chapter 1: Incidence, prevalence, patient characteristics, and treatment modalities. www.usrds.org/2014/view/Default.aspx. Accessed 7 Mar 2016.

  10. Nakai S, Hanafusa N, Masakane I, Taniguchi M, Hamano T, Shoji T, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2012). Ther Apher Dial. 2014;18:535–602.

    Article  PubMed  Google Scholar 

  11. Prischl FC, Auinger M, Säemann M, Mayer G, Rosenkranz AR, Wallner M, Kramar R, Austrian Dialysis and Transplant Registry. Diabetes-related end stage renal disease in Austria 1965–2013. Nephrol Dial Transplant. 2015;30:1920–7.

    Google Scholar 

  12. Pippias M, Jager KJ, Kramer A, Leivestad T, Sánchez MB, Caskey FJ, et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2016;31(5):831–41.

    Google Scholar 

  13. Pippias M, Stel VS, Abad Diez JM, Afentakis N, Herrero-Calvo JA, Arias M, et al. Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry annual report. Clin Kidney J. 2015;8:248–61.

    Article  PubMed  PubMed Central  Google Scholar 

  14. European Renal Association (ERA)-European Dialysis and Transplant Association Registry (EDTA). ERA-EDTA Registry Annual Report 2012. Academic Medical Center, Department of Medical Informatics, Amsterdam, 2014. www.era-edta-reg.org/files/annualreports/pdf/AnnRep2012.pdf. Accessed 7 Mar 2016.

  15. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L, et al. Trends in death rates among US adults with and without diabetes between 1997 and 2006. Diabetes Care. 2012;35:1252–7.

    Article  PubMed  PubMed Central  Google Scholar 

  16. deBoer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. J Am Med Assoc. 2011;305:2532–9.

    Article  CAS  Google Scholar 

  17. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type 1 and type 2 diabetes mellitus. Nephrol Dial Transplant. 1994;9:1097–102.

    CAS  PubMed  Google Scholar 

  18. Teng J, Dwyer KM, Hill P, See E, Ekinci EI, Jerums G, et al. Spectrum of renal disease in diabetes. Nephrology. 2014;19:528–36.

    Article  PubMed  Google Scholar 

  19. Schernthaner G, Ritz E, Schernthaner GH. Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant. 2010;25:2044–7.

    Article  PubMed  Google Scholar 

  20. Arnouts P, Bolignano D, Nistor I, Bilo H, Gnudi L, Heaf J, et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrol Dial Transplant. 2014;29:1284–300.

    Article  CAS  PubMed  Google Scholar 

  21. Avogaro A, Schernthaner G. Achieving glycemic control in patients with type 2 diabetes and renal impairment. Acta Diabetol. 2013;50:283–91.

    Article  CAS  PubMed  Google Scholar 

  22. Groop PH, Del Prato S, Taskinen MR, Owens DR, Gong Y, Crowe S, et al. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab. 2014;16:560–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M, Woerle HJ. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years. Diabetes Obes Metab. 2014;16:1078–86.

    Article  CAS  PubMed  Google Scholar 

  24. Whalen K, Miller S, Onge ES. The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther. 2015;37:1150–66.

    Article  CAS  PubMed  Google Scholar 

  25. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gilbert RE. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int. 2014;86:693–700.

    Article  CAS  PubMed  Google Scholar 

  27. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

    Article  CAS  PubMed  Google Scholar 

  28. Wanner C, Lachin JM, Fitchett DH, Inzucchi SE, von Eynatten M, Mattheus M, et al. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease. JASN. 2015;26(Suppl B1):1133.

    Google Scholar 

  29. Schernthaner G, Schernthaner-Reiter MH. Therapy: risk of metformin use in patients with T2DM and advanced CKD. Nat Rev Endocrinol. 2015;11:697–9.

    Article  CAS  PubMed  Google Scholar 

  30. Hung SC, Chang YK, Liu JS, Hsu CC, Tarng DC. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 2015;3:605–14.

    Article  CAS  PubMed  Google Scholar 

  31. Roussel R, Lorraine J, Rodriguez A, Salaun-Martin C. Overview of data concerning the safe use of antihyperglycemic medications in type 2 diabetes mellitus and chronic kidney disease. Adv Ther. 2015;32:1029–64.

    Article  CAS  PubMed  Google Scholar 

  32. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001;24:909–13.

    Article  CAS  PubMed  Google Scholar 

  33. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care. 2006;29:1496–500.

    Article  PubMed  Google Scholar 

  34. Hayashino Y, Fukuhara S, Akiba T, Akizawa T, Asano Y, Saito A, et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia. 2007;50:1170–7.

    Article  CAS  PubMed  Google Scholar 

  35. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30:1049–55.

    Article  PubMed  Google Scholar 

  36. Drechsler C, Krane V, Ritz E, März W, Wanner C. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation. 2009;120:2421–8.

    Article  CAS  PubMed  Google Scholar 

  37. Hill CJ, Maxwell AP, Cardwell CR, Freeman BI, Tonelli M, Emoto M, et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am J Kidney Dis. 2014;63:84–94.

    Article  CAS  PubMed  Google Scholar 

  38. Adler A, Casula A, Steenkamp R, Fogarty D, Wilkie M, Tomlinson L, et al. Association between glycemia and mortality in diabetic individuals on renal replacement therapy in the U.K. Diabetes Care. 2014;37:1304–11.

    Article  CAS  PubMed  Google Scholar 

  39. Le Feuvre C, Borentain M, Beygui F, Helft G, Batisse JP, Metzger JP. Comparison of short- and long-term outcomes of coronary angioplasty in patients with and without diabetes mellitus and with and without hemodialysis. Am J Cardiol. 2003;92:721–5.

    Article  PubMed  Google Scholar 

  40. Momose M, Babazono T, Kondo C, Kobayashi H, Nakajima T, Kusakabe K. Prognostic significance of stress myocardial ECG-gated perfusion imaging in asymptomatic patients with diabetic chronic kidney disease on initiation of haemodialysis. Eur J Nucl Med Mol Imaging. 2009;36:1315–21.

    Article  PubMed  Google Scholar 

  41. Sánchez-Perales C, Vázquez E, García-Cortés MJ, Borrego J, Polaina M, Guitierrez CP, et al. Ischaemic stroke in incident dialysis patients. Nephrol Dial Transplant. 2010;25:3343–8.

    Article  PubMed  Google Scholar 

  42. Davenport A, Cox C, Thuraisingham R. Blood pressure control and symptomatic intradialytic hypotension in diabetic haemodialysis patients: a cross-sectional survey. Nephron Clin Pract. 2008;109:c65–71.

    Article  PubMed  Google Scholar 

  43. Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38:696–705.

    CAS  PubMed  Google Scholar 

  44. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30:2773–8.

    Article  CAS  PubMed  Google Scholar 

  45. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19:182–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.

    Article  Google Scholar 

  47. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–76.

    Article  CAS  PubMed  Google Scholar 

  48. Green JB, Bethel A, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–42.

    Article  CAS  PubMed  Google Scholar 

  49. Kidney Disease International Global Outcomes (KDIGO). Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012;Suppl 2:337–414.

    Google Scholar 

  50. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.

    Article  CAS  PubMed  Google Scholar 

  51. Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:f6008.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–56.

    Article  CAS  PubMed  Google Scholar 

  53. Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol. 2013;24:979–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263–75.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303–9.

    Article  CAS  PubMed  Google Scholar 

  56. Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, et al; SHARP Collaborative Group. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25:1825–33.

    Google Scholar 

  57. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.

    Article  PubMed  Google Scholar 

  58. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.

    Article  CAS  PubMed  Google Scholar 

  59. März W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011;6:1316–25.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646–61.

    Article  CAS  PubMed  Google Scholar 

  62. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Collaborative Working Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.

    Article  CAS  PubMed  Google Scholar 

  63. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al., ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393–404.

    Google Scholar 

  64. American Diabetes Association. Cardiovascular disease and risk management. Sec.8. In: Standards of medical care in diabetes – 2016. Diabetes Care. 2016;39(Suppl. 1):S60–71.

    Google Scholar 

  65. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summary. Endocr Pract. 2016;22:84–113.

    Article  PubMed  Google Scholar 

  66. Fogari R, Corradi L, Zoppi A, Lazzari P, Mugellini A, Preti P, et al. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am J Hypertension. 2007;20:1092–6.

    Article  CAS  Google Scholar 

  67. Hermida R, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood pressure lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34:1270–6.

    Article  PubMed  PubMed Central  Google Scholar 

  68. deZeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492–503.

    Google Scholar 

  69. Zoja C, Benigni A, Remuzzi G. The Nrf2 pathway in the progression of kidney disease. Nephrol Dial Transplant. 2014;29 Suppl 1:i19–24.

    Article  CAS  PubMed  Google Scholar 

  70. National Kidney Foundation. KDOQI clinical practice guidelines for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015;66:884–930.

    Google Scholar 

  71. Tattersall J, Dekker F, Heimbürger O, Jager KJ, Lameire N, Lindley E, et al.; ERBP Advisory Board. When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. Nephrol Dial Transplant. 2011;26:2082–6.

    Google Scholar 

  72. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, et al; IDEAL Study. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363:609–19.

    Google Scholar 

  73. Murtagh FE, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant. 2007;22:1955–62.

    Article  PubMed  Google Scholar 

  74. Chang TI, Shilane D, Kazi DS, Montez-Rath ME, Hlatky MA, Winkelmayer WC. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol. 2012;23:2042–9.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Foley RN, Murray AM, Li S, Herzog CA, McBean Am, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–95.

    Google Scholar 

  76. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–39.

    Article  CAS  PubMed  Google Scholar 

  77. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation. 2002;74:1377–81.

    Article  PubMed  Google Scholar 

  78. Son YK, Oh JS, Kim SM, Jm J, Shin YH, Kim JK. Clinical outcome of preemptive kidney transplantation in patients with diabetes mellitus. Transplant Proc. 2010;42:3497–502.

    Article  CAS  PubMed  Google Scholar 

  79. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61:827–37.

    CAS  PubMed  Google Scholar 

  80. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud. 2011;8:6–16.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Lindahl JP, Hartmann A, Aakhus S, Endresen K, Midtvedt K, Holdass H, et al. Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation. Diabetologia. 2016;59(4):844–52.

    Google Scholar 

  82. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011;378:1419–27.

    Article  PubMed  Google Scholar 

  83. Gruessner AC, Gruessner RW. Declining numbers of pancreas transplantations but significant improvements in outcome. Transplant Proc. 2014;46:1936–7.

    Article  CAS  PubMed  Google Scholar 

  84. Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972–82.

    Article  PubMed  Google Scholar 

  85. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720–32.

    Article  CAS  PubMed  Google Scholar 

  86. Fourtounas C. Transplant options for patients with type 2 diabetes and chronic kidney disease. World J Transplant. 2014;4:102–10.

    PubMed  PubMed Central  Google Scholar 

  87. Margreiter C, Resch T, Oberhuber R, Aigner F, Maier H, Sucher R, et al. Combined pancreas-kidney transplantation for patients with end-stage nephropathy caused by type-2 diabetes mellitus. Transplantation. 2013;95:1030–6.

    Article  CAS  PubMed  Google Scholar 

  88. Light JA, Barhyte DY. Simultaneous pancreas-kidney transplants in type I and type II diabetic patients with end-stage renal disease: similar 10-year out-comes. Transplant Proc. 2005;37:1283–4.

    Article  CAS  PubMed  Google Scholar 

  89. Light J, Tucker M. Simultaneous pancreas kidney transplants in diabetic patients with end-stage renal disease: the 20-yr experience. Clin Transplant. 2013;27:E256–63.

    Article  PubMed  Google Scholar 

  90. Redfield RR, Scalea JR, Odorico JS. Simultaneous pancreas and kidney transplantation: current trends and future directions. Curr Opin Organ Transplant. 2015;20:94–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rudolfstiftung Hospital-Vienna, Wien, Austria

    Guntram Schernthaner

  2. Klinikum Wels-Grieskirchen, Wels, Austria

    Friedrich C. Prischl

Authors
  1. Guntram Schernthaner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Friedrich C. Prischl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Schernthaner, G., Prischl, F.C. (2017). Management of Overt Diabetic Kidney Disease and Uremia. In: Managing Diabetic Nephropathies in Clinical Practice. Adis, Cham. https://doi.org/10.1007/978-3-319-08873-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08873-0_5

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08872-3

  • Online ISBN: 978-3-319-08873-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation